Segment Information (Notes)

12 Months Ended

Dec. 31, 2020

Segment Reporting Disclosure [Text Block]

21. Segment Information

Information regarding the Company’s segments for the eight months ended August 31, 2020 and the year ended December 31, 2019 is as follows:


Revenues by segment	Eight Months Ended		Year Ended
(in thousands)	August 31, 2020		December 31, 2019

Medical Devices	$	15,211	$	30,742
Strategic Positions	—		—
Pharmaceutical	—		—
Income Generating Assets	110		(36)
Total revenues	$	15,321	$	30,706

________________

The table above excludes revenues related to discontinued operations. See Note 4, Discontinued Operations Classified as Assets Held for Sale, for additional information.


(Loss) income by segment	Eight Months Ended		Year Ended
(in thousands)	August 31, 2020		December 31, 2019

Medical Devices	$	(4,454)	$	(5,230)
Strategic Positions	(15,723)		28,758
Pharmaceutical (1)	(15,855)		(19,048)
Income Generating Assets (1)	(37,217)		(74,891)
Total	(73,249)		(70,411)
Change in fair value of warrants not allocated to segments (2)	(4,047)		—
Total net loss	$	(77,296)	$	(70,411)

________________

(1) The (Loss) income by segment presented above includes amounts related to both continuing and discontinued operations. See Note 4, Discontinued Operations Classified as Assets Held for Sale, for additional information.

(2) The change in fair value of warrants not allocated to segments presented above includes the amounts related to the change in fair value of the Evofem warrants after the distribution of the Evofem common stock to PDL stockholders on May 21, 2020. The Strategic Positions segment ceased to be a reporting segment as of this date.


Long-lived assets by segment	Year Ended
(in thousands)	December 31, 2019

Medical Devices	$	2,435
Strategic Positions	—
Pharmaceutical (1)	2,960
Income Generating Assets	125
Total long-lived assets	$	5,520

________________

(1) The amounts above include Property and Equipment in the Pharmaceutical segment classified as Assets held for sale. See Note 4, Discontinued Operations Classified as Assets Held for Sale, for additional information.

The operations for the Medical Devices segment were primarily located in the United States and the operations for the Pharmaceutical segment were primarily located in Italy, Ireland and the United States.